Post-Authorization Safety Surveillance of KIOVIG (Human Normal Immunoglobulin 10% Liquid, Baxter) in an Open, Uncontrolled, Non-Interventional, Observational Cohort Study in Immunodeficiency and Autoimmune Diseases

被引：0
|
作者：
Misbah, S. [1 ]
Soler-Palacn, P. [2 ]
Mccoy, B. [3 ]
Engl, W. [3 ]
Empson, V. [3 ]
Nikolov, N. [4 ]
机构：
[1] John Radcliffe Hosp, Acad Ctr L4, Oxford OX3 9DU, England
[2] Hosp Univ Vall dHebron, Pediat Infect Dis & Immunodeficiencies Unit, Barcelona, Spain
[3] Baxter Healthcare, BioSci, Vienna, Austria
[4] Baxter Healthcare SA, BioSci, Zurich, Switzerland
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
ESID-0139
引用
收藏
页码：S294 / S295
页数：2
相关论文
共 11 条
  • [1] Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study
    Blazek, Bohumir
    Misbah, Siraj A.
    Soler-Palacin, Pere
    McCoy, Barbara
    Leibl, Heinz
    Engl, Werner
    Empson, Victoria
    Gelmont, David
    Nikolov, Nikolai
    IMMUNOTHERAPY, 2015, 7 (07) : 753 - 763
  • [2] A GLOBAL NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) OF HYQVIA IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD)
    Rubenstein, Arye
    Bridges, Tracy
    McNeil, Donald
    Tachdjian, Raffi
    Wedner, H. James
    Wasserman, Richard L.
    Leibl, Heinz
    Rabbat, Christopher
    Honigberg, Robert
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 216 - 217
  • [3] Preliminary findings from a non-interventional post-authorization safety study (PASS) for active safety surveillance of comirnaty vaccine recipients in the EU
    Wong, Cherise
    Kendrick, Katherine
    Rubino, Heather
    Zaccai, Julia
    Castro, Clara
    Negreiro, Filipa
    Santos, Carolina
    Thakar, Jaydip
    Yakushev, Alexander
    Haith, Emerald
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 591 - 591
  • [4] POST-AUTHORIZATION SAFETY STUDY OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% TREATMENT IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
    Rubinstein, A.
    Bridges, T.
    McNeil, D.
    Tachdjian, R.
    Wedner, H.
    Wasserman, R.
    Leibl, H.
    Rabbat, C.
    Honigberg, R.
    Yel, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S71 - S71
  • [5] INTERIM RESULTS OF A NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) ON THE LONG-TERM SAFETY OF SCIG 10% INFUSION FACILITATED WITH RECOMBINANT HUMAN HYALURONIDASE (rHUPH20) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) IN EUROPE (EU)
    Ellerbroek, Pauline
    Hanitsch, Leif
    Schmidt, Reinhold
    van Hagen, P. M.
    van Paassen, Pieter
    Borte, Michael
    Berner, Todd
    Nikolov, Nikolai
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 (02) : 216 - 216
  • [6] Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study
    Rubinstein, Arye
    Bridges, Tracy A.
    Wedner, H. James
    McNeil, Donald
    Wasserman, Richard L.
    Tachdjian, Raffi
    Stryk, Steven V.
    Tarpay, Martha M.
    Fielhauer, Katharina
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB117 - AB117
  • [7] Kiovig (Human Normal Immunoglobulin 10% Liquid) in Pediatric Immune Thrombocytopenia (ITP): Safety and Efficacy Data from a Prospective, International, Non-Controlled, Observational Study
    Blazek, B.
    Hermann, C.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Nikolov, N.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S295 - S295
  • [8] Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA
    Rubinstein, Arye
    Mabudian, Mohsen
    McNeil, Donald
    Patel, Niraj
    Wasserman, Richard
    Gupta, Sudhir
    Carrasco, Paz
    Nagy, Andras
    Yel, Leman
    CLINICAL IMMUNOLOGY, 2023, 250 : 36 - 37
  • [9] Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study
    Rubinstein, Arye
    Mabudian, Mohsen
    Mcneil, Donald
    Patel, Niraj C.
    Wasserman, Richard L.
    Gupta, Sudhir
    Carrasco, Paz
    Chen, Jie
    Garcia, Enrique
    Nagy, Andras
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (08)
  • [10] An open-label, non-comparative, non-interventional, multi-center, post-authorization safety study on the administration of rabeprazole to adults with gastro-esophageal reflux disease
    Zouboulis-Vafiadis, Irini
    Paraskevas, Emmanuel
    Tzourmakliotis, Dimitrios
    Hatzikyriakou, Maria
    Mestoussi, Angeliki
    Vasdekis, Vassilios
    Katsilabros, Nikolaos
    Arhimandritis, Athanasios
    Papadokostopoulou, Alexandra
    ANNALS OF GASTROENTEROLOGY, 2014, 27 (02): : 133 - 138
12